Leading the way in clean technology, BioLargo Inc.'s (BLGO:OTCQX) President and CEO Dennis P. Calvert shared an open letter to shareholders reflecting on 2025 and anticipating the company's role in "what may be one of the largest infrastructure and technology investment cycles in history."
"Global investment trends driven by artificial intelligence, data centers, electrification, energy storage, and environmental remediation are placing increasing demands on water systems, energy infrastructure, and regulatory compliance," Calvert observed. "BioLargo's portfolio of enabling technologies has been developed to address these challenges at the system level, where performance, sustainability, and economics increasingly converge."
Throughout 2025, BioLargo advanced multiple technology platforms through ongoing development, validation, and initial deployment efforts, Calvert noted. Management deliberately prioritized strategic advancement over rapid expansion, understanding that swift growth is most effective when supported by a solid technical and commercial foundation. This focus on capital efficiency and technical precision is intended to facilitate faster, lower-risk scaling as market adoption increases.
"This approach reflects BioLargo's long-standing strategy to develop high-impact technologies patiently, validate them thoroughly, and position them to serve large and growing markets where demand is driven by structural forces rather than short-term trends," Calvert stated.
In 2025, BioLargo advanced several projects in New Jersey that demonstrate the company's transition from development to real-world application, according to the letter. First, these projects include the installation of the company's proprietary Aqueous Electrostatic Concentrator (AEC) at a municipal water treatment facility in Lake Stockholm, New Jersey. The AEC provides rapid, effective, and affordable concentration and removal of per- and polyfluoroalkyl substances (PFAS) from water.
The company is also working to formalize a budding public-private partnership that could lead to the construction and operation of one or more Cellinity battery factories aligned with state and regional infrastructure priorities, the letter indicated.
Finally, Clyra Medical has made significant capital investments with its contract manufacturing partner in the region to expand operational capacity for Clyra's anticipated launch of its medical device products, expected in 2026.
"While these initiatives remain subject to further development and execution, they represent tangible progress toward deployment and reflect growing institutional engagement with BioLargo's technologies," Calvert wrote. "It is also worth noting that BioLargo's engineering team has a long and successful history of working with industry and governments in the State of New Jersey."
Alignment with a Historic Investment Cycle
BioLargo's energy and environmental technologies are increasingly in sync with the demands of industries central to global capital investment, the CEO highlighted. Data centers and advanced manufacturing facilities are facing mounting challenges related to water usage, emissions, energy efficiency, and regulatory compliance. Energy storage systems like lithium-ion are meeting resistance in local communities due to safety concerns and environmental impact.
"BioLargo's energy and environmental solution — Cellinity® — is designed to support more efficient, sustainable, safe, and compliant system-level performance as scale and regulatory requirements increase," the letter stated. "At the same time, BioLargo ushers in a domestic production alternative just as global and domestic priorities are increasingly focused on reducing and reshaping geopolitical supply-chain constraints that affect the energy and energy-storage industries."
In 2025, Clyra Medical Technologies continued to progress through coordinated commercial, product development, and clinical engagement activities, according to the company. What started as a research-intensive endeavor to transform BioLargo's proprietary iodine-based technology into groundbreaking medical products has evolved into a commercial-stage platform supported by multiple development and market-entry initiatives.
Clyra recently completed its initial production run for the non-surgical wound irrigation solution ViaClyr, with medical products distributor Advanced Solution under contract and preparing for market entry, Calvert mentioned. Additionally, Clyra's surgical products are aimed for commercial launch shortly thereafter. Concurrently, expanded product designs are being developed to support additional clinical and commercial applications like dental, wound dressings, and more.
Clinical work is also being conducted by some of Clyra's key opinion leaders (KOLs), providing real-world application experience and evidence that will assist medical professionals in understanding the safety and efficacy of the products as they seek the best and newest treatment alternatives for their patients, the letter noted. Clyra's KOLs will present clinical findings at medical symposiums in early 2026, subject to customary clinical, regulatory, and publication considerations.
"Based on current progress, BioLargo believes 2026 has the potential to represent a period of meaningful revenue contribution from Clyra as well as clinical and market validation of Clyra's products and BioLargo's technologies," Calvert wrote. "Management views this as an important milestone in the platform's evolution from development into active commercialization."
Looking Ahead
As BioLargo enters 2026, global priorities related to infrastructure expansion, energy storage, environmental remediation, and medical innovations for human health continue to evolve and advance, Calvert mentioned. With several technology platforms maturing and approaching readiness for commercial adoption, alongside progressing early deployment initiatives, the company believes it is increasingly aligned with these global priorities and will be well-positioned to capture global attention and achieve commercial success.
"While the timing and scale of market adoption is always uncertain, BioLargo remains focused on executing its strategy and advancing its technologies responsibly," he wrote. "In management's view, the company enters the next phase of its development with the right technologies, the right teams, a disciplined strategy, and timing that is increasingly aligned with years of preparation."
Expert 'Hot' On Company's Long-Term Prospects
Chris Temple from The National Investor expressed his views on the company following a recent announcement about the AEC's performance, stating, "BioLargo announced that its regimen to remove PFAS 'forever chemicals' from water is even more robust."
Temple also disclosed his plan to visit the energy division in Oak Ridge, Tennessee, where the company is developing its new battery technology. "I've been very hot on the long-term prospects of this company, notwithstanding the reality that pitfalls here and there have kept BioLargo's share price somewhat hobbled," Temple remarked during an online interview with Calvert and Steve Harrison, President of BioLargo subsidiary Clyra Medical Technologies, on November 20. "We've seen a couple of times in the last year or so some rallies and then setbacks."
Additionally, Richard Ryan, an analyst with Oak Ridge Financial, has highlighted, "The large emerging market for PFAS removal and BLGO's growing validation in this opportunity should not be overlooked." Ryan reiterated his Buy rating on the stock on November 19.
The Catalysts: Multiple Opportunities for the Company
The PFAS filtration market is expected to grow from US$2.13 billion in 2025 to US$2.99 billion by 2030, with a compound annual growth rate (CAGR) of 7% during this time frame, according to a report by Markets and Markets. This growth is largely driven by increasing awareness of the serious health and environmental risks posed by PFAS. These chemicals are highly persistent and have been linked to cancer, hormone disruption, immune system effects, and other chronic health issues. Consequently, governments worldwide, particularly in North America, Europe, and parts of Asia, are implementing stricter regulations on PFAS levels in drinking water, industrial wastewater, and consumer products. These regulatory measures are prompting municipalities and industries to invest in technologies capable of removing PFAS. The primary drivers of market growth include increasing health and environmental concerns, stricter environmental regulations, and a rising demand for clean and safe drinking water.
According to Grand View Research, regulatory bodies like the U.S. Environmental Protection Agency (EPA) and the European Chemicals Agency (ECHA) are enforcing stricter limits on PFAS concentrations in drinking water, pushing municipalities and industries to adopt advanced treatment technologies. Increased investments in wastewater infrastructure, along with technological advancements in adsorption, membrane filtration, and destruction processes, are enhancing market adoption across industrial, commercial, and municipal sectors.
"The market presents significant growth opportunities driven by increasing investments in advanced remediation technologies and the emergence of sustainable treatment materials," Grand View stated. "The rising focus on green chemistry and circular economy principles is fostering the development of eco-friendly adsorbents, regenerable resins, and PFAS destruction methods such as plasma and electrochemical oxidation."
The global demand for grid-scale energy storage is rapidly growing to support increasing needs. In 2024, the U.S. Energy Information Administration (EIA) reported a 66% rise in battery energy storage capacity within the United States. While lithium-ion batteries currently lead this sector, they present several challenges, such as fire risks due to thermal runaway, efficiency loss over time, and sourcing difficulties related to rare and critical minerals. BioLargo stated that its Cellinity battery technology tackles these issues by using innovative materials and designs to deliver exceptional thermal performance and operational efficiency without relying on rare earth elements. According to a February report by the International Energy Agency (IEA), global electricity consumption is expected to grow at its fastest rate in recent years, increasing by nearly 4% annually through 2027 as power use rises across various sectors.
Streetwise Ownership Overview*According to Future Market Insights, the global market for anti-biofilm wound dressings is projected to grow at a compound annual growth rate (CAGR) of 9.8% from 2025 to 2035, reaching US$2.4 billion from US$943.5 million. This expansion is primarily driven by the increasing incidence of surgical site infections, diabetic ulcers, and chronic wounds. Biofilms, which contribute to antibiotic resistance and slow healing, are also a major concern. In the United States, the market is expected to grow significantly, with a projected CAGR of 9.3% during the forecast period. This growth is fueled by the prevalence of chronic wounds, an aging population, the demand for advanced care, technological advancements, and government initiatives, according to the research firm.
Ownership and Share Structure1
Approximately 13.79% of BioLargo is owned by insiders and management. This includes Chief Science Officer Kenneth Code with 8.17%, CEO Calvert with 3.3%, and Director Jack Strommen with 1.56%.
About 0.04% is held by the institution First American Trust. The remaining 86% is owned by retail investors.
The company's market cap is US$54.97 million, with approximately 313.76 million shares outstanding and about 270.51 million free-floating. It trades within a 52-week range of US$0.32 and US$0.14.
| Want to be the first to know about interesting Clean Energy, Biotechnology / Pharmaceuticals and Technology investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
- Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
- Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
